Brought to you by 
Hoechst Marion Roussel to market Teva's MS drug
11 Feb 2002
Executive Summary
Hoechst's pharmaceutical unit Hoechst Marion Roussel has expanded its deal from earlier this year with Teva Pharmaceutical Industries to include Europe and other markets for Teva's investigational multiple sclerosis drug Copaxone.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Hoechst Marion Roussel to market Teva's MS drug
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice